Our Services
Medical Information
Helpful Resources
Published on: 10/26/2026
Xarelto (rivaroxaban) raises bleeding risk, and certain signs call for urgent medical review: bleeding that will not stop, red or black tarry stools, pink or brown urine, vomiting or coughing up blood, unusual bruising, or heavy nosebleeds. Severe headache, sudden dizziness, weakness, confusion, vision changes, or numbness may signal bleeding in or around the brain and warrant emergency care, as can back pain or leg weakness after spinal procedures. Milder issues like easy bruising or longer bleeding from small cuts are common, but drug interactions, kidney function, missed doses, and age all change how serious symptoms become, so there are several important factors to consider before deciding whether to wait or seek help immediately. Because bleeding symptoms overlap with many other conditions, a free, instant, online symptom check can help you organize what you are feeling and understand which next step fits your situation. See the complete details below, then use it to prepare for a focused conversation with your doctor or pharmacist.
Last reviewed for medical accuracy: 10/22/2026
Xarelto (rivaroxaban) is a widely prescribed blood thinner used to prevent and treat blood clots. Like all anticoagulants, it carries certain risks—most notably bleeding. Understanding the side effects of Xarelto and recognizing bleeding signs that need urgent review can help you stay safe while benefiting from its clot-preventing action.
Xarelto works by blocking a key protein in the clotting process. It’s commonly prescribed for:
Its convenience as a once-daily pill makes it popular, but no blood thinner is without potential drawbacks. Being aware of the side effects of Xarelto—especially bleeding—can help you spot problems early.
Because Xarelto reduces your blood’s ability to clot, you may bleed more easily. For many, this means:
However, sometimes bleeding can be more serious. It might be internal (you can’t see it) or external, and it can involve critical areas like your brain or gastrointestinal tract. Prompt attention to warning signs can prevent complications.
Bleeding on Xarelto ranges from mild to life threatening. Here’s how to tell the difference:
These are usually not emergencies but do keep an eye on them. If they worsen or become more frequent, let your doctor know.
Immediately seek medical advice if you notice:
These signs can point to internal bleeding. If any of these occur, treat them as an urgent matter.
While bleeding is the most serious concern, you may experience other side effects. Common ones include:
Most of these are mild and improve as your body adjusts. Still, if they persist or worsen, discuss them with your healthcare provider.
Documenting your symptoms helps your care team decide whether to adjust your Xarelto dose or switch medications.
By staying proactive, you minimize risks and help health professionals act quickly if bleeding occurs.
If you’re ever unsure whether your symptoms are serious, consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker. It’s a simple, confidential way to gauge your symptoms and decide if you need to seek immediate care.
Always keep an open line of communication with your healthcare provider. Schedule regular follow-ups to review:
Never hesitate to “err on the side of caution.” If you experience anything that could be life threatening or serious—especially the bleeding signs listed above—contact your doctor or seek emergency care right away.
The side effects of Xarelto can be managed safely when you know what to look for. By staying alert to bleeding signs, following dosing instructions, and using the resources available—like the Ubie Symptom Checker—you can reduce risks and focus on the benefits of your treatment. Always prioritize your health and speak to a doctor about any concerns.
(References)
* Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10. PMID: 21830957.
* Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med. 2013 Jul;80(7):443-51. doi: 10.3949/ccjm.80a.13025. PMID: 23821689.
* Kawada T. Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin. Eur J Intern Med. 2017 Mar;38:e20. doi: 10.1016/j.ejim.2016.11.016. PMID: 27916438.
* Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P, EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017 Mar 30;376(13):1211-1222. doi: 10.1056/NEJMoa1700518. Epub 2017 Mar 18. PMID: 28316279.
* Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S, COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27. PMID: 28844192.
* Bode C, Olivier CB, Duerschmied D. Is Bleeding Always Bad?: Bad Boy Bleeding. J Am Coll Cardiol. 2019 Sep 24;74(12):1529-1531. doi: 10.1016/j.jacc.2019.07.066. PMID: 31537260.
* Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, Hess CN, Pap AF, Kittelson JM, Gudz I, Mátyás L, Krievins DK, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020 May 21;382(21):1994-2004. doi: 10.1056/NEJMoa2000052. Epub 2020 Mar 28. PMID: 32222135.
* Fernández MS, Marín F, Rafols C, Arribas F, Barrios V, Cosín-Sales J, Sánchez MA, the EMIR Study Investigators:. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study). J Comp Eff Res. 2021 May;10(7):583-593. doi: 10.2217/cer-2020-0286. Epub 2021 Mar 31. PMID: 33787316.
* Raskob GE, Ageno W, Albers G, Elliott CG, Halperin J, Maynard G, Steg PG, Weitz JI, Albanese J, Yuan Z, Levitan B, Lu W, Suh EY, Spiro T, Lipardi C, Barnathan ES, Spyropoulos AC. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. J Am Heart Assoc. 2022 Oct 18;11(20):e026229. doi: 10.1161/JAHA.122.026229. Epub 2022 Oct 7. PMID: 36205248; PMCID: PMC9673674.
* Castellucci LA, Chen VM, Kovacs MJ, Lazo-Langner A, Greenstreet P, Kahn S, Côté B, Schulman S, de Wit K, Douketis J, Suryanarayan D, Wan T, Yeo E, Le Templier G, Tran HA, Willcox A, Crowther HJ, Prasad R, Shivakumar S, Umana E, Ni Ainle F, Tritschler T, Barco S, Galanaud JP, Blondon M, Baumann Kreuziger L, Solymoss S, Kearon C, Thomas E, Ramsay T, Le Gal G, Rodger M, COBRRA Trial Investigators. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism. N Engl J Med. 2026 Mar 12;394(11):1051-1060. doi: 10.1056/NEJMoa2510703. PMID: 41812192.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.